title: Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Florence
authors.initials: F
authors.lastname: Butlen-Ducuing
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Frank
authors.initials: F
authors.lastname: Pétavy
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Guizzaro
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Zienowicz
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Manuel
authors.initials: M
authors.lastname: Haas
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Enrica
authors.initials: E
authors.lastname: Alteri
authors.affiliation: Medical Products Agency, SE-751 03 Uppsala, Sweden, and is Chair of the CHMP.
authors.forename: Tomas
authors.initials: T
authors.lastname: Salmonson
authors.affiliation: INSERM UMR 1178, Univ Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin Bicêtre, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Corruble
mesh_terms: D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D017277:Drug Approval; D015195:Drug Design; D005062:European Union; D006077:Government Agencies; D006801:Humans
chemical_list: D002491:Central Nervous System Agents